Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Adrenergic Receptors: ɑ Subtype01:31

Adrenergic Receptors: ɑ Subtype

1.6K
Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
1.6K
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers01:22

Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers

892
α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
892
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

783
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
783
Adrenergic Agonists: Therapeutic Uses01:30

Adrenergic Agonists: Therapeutic Uses

858
Adrenergic agonists have diverse therapeutic uses across various medical conditions and emergencies.
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...
858
Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers01:17

Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers

934
Adrenergic antagonists, or sympatholytics, inhibit adrenoceptor activation driven by catecholamines or agonists. Based on their adrenoceptor specificity, adrenergic blockers can be categorized into two primary groups: α-adrenergic blockers (α-blockers) and β-adrenergic blockers (β-blockers). α-blockers interact with α1 and α2 subtypes of α-adrenoceptors.
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
934
Adrenergic Receptors: β Subtype01:26

Adrenergic Receptors: β Subtype

1.8K
β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
1.8K

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Weight-loss practices and dietary quality in Chinese adolescents.

BMC public health·2026
Same author

Propofol-based versus volatile anesthesia and postoperative immune response in prostate cancer.

Translational andrology and urology·2026
Same author

Structural insights into flexible pyruvate binding in an (S)-selective ω-transaminase.

Biochemical and biophysical research communications·2026
Same author

Efficient whole-cell biocatalytic synthesis of 2'-deoxy-2'-fluoroadenosine, a key building block for nucleic acid drugs.

Synthetic and systems biotechnology·2026
Same author

The RNAi machinery regulates lovastatin biosynthesis via microRNA-like RNAs in industrial <i>Aspergillus terreus</i>.

Synthetic and systems biotechnology·2026
Same author

Corrigendum to "TCF7L2 transcriptionally regulates C1QB to exacerbate synaptic pruning-dependent neuronal injury in the epileptic hippocampus" [Brain Res. Bull. 235 (2026) 111730].

Brain research bulletin·2026
Same journal

A Ni-Mediated Cross-Coupling Approach to Deuterated <sup>18</sup>F- Fluoromethylated (Hetero)arenes.

Journal of the American Chemical Society·2026
Same journal

Efficient Light-Driven CO<sub>2</sub> Capture and Reversible Release Enabled by Metastable Photoacid-Decorated Metal-Organic Frameworks.

Journal of the American Chemical Society·2026
Same journal

In Situ Raman Spectroscopy Reveals the Dynamic Evolution and Ethanol Dependence of SEI Structure in Li-Mediated N<sub>2</sub> Reduction Reaction.

Journal of the American Chemical Society·2026
Same journal

Solvent Esterification and Stoichiometric Control in Ambient-Grown FAPbI<sub>3</sub> Single-Crystal Solar Cells.

Journal of the American Chemical Society·2026
Same journal

Unlocking Azulene Functionalization via Strain-Induced Azulyne Intermediates.

Journal of the American Chemical Society·2026
Same journal

An Oxazine-Locked Covalent Organic Framework by a Tandem Pinner/Schiff Base Reaction for Hydrogen Peroxide Photosynthesis.

Journal of the American Chemical Society·2026
関連記事をすべて見る

関連する実験動画

Updated: Jul 27, 2025

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
11:29

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells

Published on: July 20, 2016

11.1K

アデノシンA

Jinfeng Zhang1,2, Dandan Feng1,2, Jianjun Cheng1,2

  • 1iHuman Institute, ShanghaiTech University, Shanghai 201210, China.

Journal of the American Chemical Society
|June 5, 2023
PubMed
まとめ
この要約は機械生成です。

フロリン-19核磁気共鳴 (19F-NMR) スペクトロスコピーは,Gタンパク質結合受容体 (GPCR) リガンドをスクリーニングするための新しい方法を提供します. このアプローチは,新しい探査分子を使用して,A2Aアデノシン受容体 (A2AAR) を標的とする新しい薬剤候補を発見するための強力な代替手段を提供します.

さらに関連する動画

Testing Acetylcholine Followed by Adenosine for Invasive Diagnosis of Coronary Vasomotor Disorders
05:58

Testing Acetylcholine Followed by Adenosine for Invasive Diagnosis of Coronary Vasomotor Disorders

Published on: February 3, 2021

3.6K
Author Spotlight: Advancing Cellular and Protein Engineering to Control Biological Functions and Develop Novel Therapies
04:17

Author Spotlight: Advancing Cellular and Protein Engineering to Control Biological Functions and Develop Novel Therapies

Published on: September 27, 2024

726

関連する実験動画

Last Updated: Jul 27, 2025

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
11:29

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells

Published on: July 20, 2016

11.1K
Testing Acetylcholine Followed by Adenosine for Invasive Diagnosis of Coronary Vasomotor Disorders
05:58

Testing Acetylcholine Followed by Adenosine for Invasive Diagnosis of Coronary Vasomotor Disorders

Published on: February 3, 2021

3.6K
Author Spotlight: Advancing Cellular and Protein Engineering to Control Biological Functions and Develop Novel Therapies
04:17

Author Spotlight: Advancing Cellular and Protein Engineering to Control Biological Functions and Develop Novel Therapies

Published on: September 27, 2024

726

科学分野:

  • 薬剤化学
  • バイオ物理学
  • 薬理学について

背景:

  • Gタンパク質結合受容体 (GPCR) のリガンド結合親和性は,伝統的に,放射性リガンド競争測定を用いて測定される.
  • 19F核磁気共鳴 (19F-NMR) スペクトロスコピーは,薬剤発見における小分子鉛化合物のスクリーニングのための新興技術である.
  • リガンド結合親和度およびスクリーニング化合物の測定のための既存の方法は,しばしば異なる実験条件を伴う.

研究 の 目的:

  • A2Aアデノシン受容体 (A2AAR) との結合研究のために,フッ素を含む探査分子,FPPAを開発し,検証する.
  • 薬物スクリーニングと親和度測定のための堅固な1D 19F-NMRプロトコルを確立する.
  • A2AARを標的とする新薬候補を発見するためのFPPAと19F-NMRの有用性を実証する.

主な方法:

  • A2AAR-V-2006複合体に基づくフッ素含有プローブ分子 (FPPA) の構造ベースの設計.
  • 1D 19F-NMR測定のための実験条件の開発.
  • 既知のA2AARリガンドを用いたFPPAベースの19F-NMRプロトコルの検証

主要な成果:

  • A2AAR結合研究のために,新しいフッ素を含む探査分子,FPPAが成功裏に設計されました.
  • FPPAを用いた1D 19F-NMRプロトコルが,薬剤スクリーニングと親和度測定のために確立された.
  • この方法は,既知のA2AARリガンドを特定する際の強度を示した.

結論:

  • FPPAプローブによる19F-NMRスペクトロスコピーは,A2AARリガンド発見のための伝統的な放射性リガンドアッセイの実行可能で堅固な代替手段です.
  • このアプローチは,薬剤候補のスクリーニングを容易にし,A2AARを標的とする潜在的な治療法のライブラリを拡張します.
  • この方法論は,新しいコア構造を持つリガンドを発見するのに有望である.